About the Company
rapt therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. rapt has discovered and advanced two unique drug candidates, flx475 and rpt193, each targeting c-c motif chemokine receptor 4 (ccr4), for the treatment of cancer and inflammation, respectively. the company is also pursuing a range of targets that are in the discovery stage of development.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
137
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RAPT News
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and ...
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
Investors are always looking for stocks that are poised to beat at earnings season and RAPT Therapeutics, Inc. RAPT may be one such company. The firm has earnings coming up pretty soon, and events are ...
RAPT Apr 2024 10.000 put
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based ...
Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns
In a report released on March 7, Thomas Smith from Leerink Partners maintained a Hold rating on RAPT Therapeutics (RAPT – Research ...
RAPT Oct 2024 5.000 call
Company maintains solid cash position of $158.9 millionSOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT
New York, New York-- (Newsfile Corp. - March 5, 2024) - Pomerantz LLP is investigating claims on behalf of investors of RAPT Therapeutics, Inc. ("RAPT" or the "Company") (NASDAQ: RAPT). Such investors ...
RAPT Therapeutics GAAP EPS of -$0.80
Net loss for the fourth quarter of 2023 was $30.9 million, compared to $23.0 million for the fourth quarter of 2022. As of December 31, 2023, the Company had cash and cash equivalents and marketable ...
RAPT Therapeutics: Q4 Earnings Insights
RAPT Therapeutics RAPT reported its Q4 earnings results on Thursday, March 7, 2024 at 08:00 AM. Here's what investors need to know about the announcement. RAPT Therapeutics beat estimated earnings by ...
Earnings Outlook For Relmada Therapeutics
Analysts estimate that Relmada Therapeutics will report an earnings per share (EPS) of $-0.83. Relmada Therapeutics bulls ...
Sight Sciences, Inc.
Sight Sciences, Inc. is an ophthalmic medical device company, which focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye ...
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics ( SRPT 1.48%) could have a serious new competitor on the horizon. According to some fresh clinical data ...
RAPT Therapeutics, Inc.: RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and ...
Loading the latest forecasts...